Fiasp® (insulin aspart, Novo Nordisk) is a faster-acting injectable insulin formulation that is administered subcutaneously (SC) for blood glucose management. We hypothesized that intradermal (ID) administration could improve the pharmacokinetic profile of Fiasp® when compared to traditional SC injection.

Herein, we describe a simple, scalable and cost-effective hollow microneedle platform to evaluate the effects of ID administration on Fiasp® pharmacokinetics. Three groups of 8 rats received 1 IU/kg by SC injection or by ID injection using either a single or quadruple microneedle projection design. Blood was collected from 5-240 mins post-injection and assayed for insulin (ELISA, Crystal Chem) and blood glucose (hand-held glucometer) concentrations.

The results (below) show that plasma insulin levels were comparable for all groups with mean values ranging from 464 to 480 µU/mL. Yet, the peak plasma concentrations were 1.5-3-fold earlier for rats treated using the microneedle designs. This preliminary data suggests that ID injection of Fiasp® using these novel hollow microneedle designs results in faster absorption and thereby could lead to a more rapid onset of action.

Disclosure

S. Ranamukha: None. I. Mansoor: Stock/Shareholder; Self; Microdermics. K. Feng: Employee; Self; Microdermics Inc. B. Stoeber: Other Relationship; Self; Microdermics Inc.. M. Wehbe: None. R. St Clair: Employee; Self; Microdermics Inc. C. Piche: Employee; Self; Locemia Solutions. Stock/Shareholder; Self; Locemia Solutions. Consultant; Self; Microdermics Inc. Stock/Shareholder; Self; Diasome Pharmaceuticals, Inc., Bigfoot Biomedical. J. Moreau: Consultant; Self; Microdermics.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.